-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
FSL-1-TFA
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/fsl-1-tfa.gif)
| Category | Herpes simplex Virus (HSV) |
| Description | FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection. |
Product Information
| Synonyms | FSL-1 (TFA)|CS-0130017 |
| Molecular Weight | 1780.18 |
| Molecular Formula | C82H141F3N14O20S |
| Boiling Point | 1659.8±65.0 °C at 760 mmHg |
| Flash Point | 957.6±34.3 °C |
| Purity | 99.58% |
| Density | 1.2±0.1 g/cm3 |
| Solubility | In Vitro: H2O |
| Appearance | White to off-white (Solid) |
| Storage | Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 years * In solvent -80°C 6 months -20°C 1 month (sealed storage, away from moisture and light) |
| Index Of Refraction | 1.553 |
| In Vitro | FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC). FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile. FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells. FSL-1 activates the MAP kinase/NF-κB signaling pathway. |
| In Vivo | FSL-1 application significantly protectes against genital HSV-2 challenge in mice. |
| Target | Toll-like Receptor (TLR); MMP; HSV; Antibiotic |
| Vapor Pressure | 0.0±0.3 mmHg at 25°C |
